[{"id":"42b6baf8-4551-4b46-9aa7-65602da4a620","acronym":"","url":"https://clinicaltrials.gov/study/NCT05733611","created_at":"2023-02-17T15:01:01.140Z","updated_at":"2024-07-02T16:35:11.814Z","phase":"Phase 2","brief_title":"RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC","source_id_and_acronym":"NCT05733611","lead_sponsor":"Replimune Inc.","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • RP3 • sturlimogene erparepvec (RP2)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 4","initiation":"Initiation: 06/29/2023","start_date":" 06/29/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-04-02"}]